Diana Do, MD, Professor of Ophthalmology, Vice Chair Clinical Affairs, Department of Ophthalmology, Stanford University, Byers Eye Institute.

In this episode, Dr. David Boyer discusses a Phase 2 trial studying intravitreal injection of retinal progenitor cells for treatment of eyes with retinitis pigmentosa.

Dr. Francois discusses the epidemiology of geographic atrophy, the pathophysiology of complement inhibition in the treatment of GA, and the latest information on Apellis' Phase 2 and Phase 3 clinical trials.

Join us in a discussion with Dr. Charles Wykoff & Karl Csaky MD, PhD on Faricimab for DME and nAMD. Interpreting the Durability Signals from the Phase 3 Programs.

Join us as Dr. Carmen Puliafito and Charles Wykoff MD, PhD speak about the results. 1 of 3 total parts to "Interpreting Faricimab Phase 3 Data in DME & nAMD"

Join us as Dr. Charles Wykoff dives in a discussion with Arshad Khanani MD, MA in a discussion on Faricimab in the TENAYA and LUCERN Phase 3 nAMD Trials: Interpreting the Results

Join us as Dr. Carmen Puliafito joins in a discussion with Carl Regillo, MD, Director of Retina Serivce, Wills Eye Institute on the topic of Phase 3 Results from the Port Delivery System (PDS) Phase 3 Trial.

Dr. Carmen Puliafito interviews Andrew Moshfeghi, MD on a topic: Tyrosine Kinase Inhibitor Delivery by Hydrogel for Treatment of Wet AMD

Michael Goldstein MD, MM Chief Medical Officer at Ocular Therapeutix also served as Co-Director, Cornea, External Disease and Cataract Service; Refractive Surgery Service; Uveitis & Immunology Service; Assistant Professor, Tufts University School of Medicine.

Spotlight on David Zacks, M.D., Ph.D. Co-Founder and Chief Science Officer at ONL Therapeutics.